Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
or

Kymera Therapeutics Inc (KYMR)

Kymera Therapeutics Inc (KYMR)
28.83 x 1 28.84 x 6
Post-market by (Cboe BZX)
28.80 +1.64 (+6.04%) 04/22/25 [NASDAQ]
28.83 x 1 28.84 x 6
Post-market 28.80 unch (unch) 16:02 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
27.50
Day High
28.97
Open 27.71
Previous Close 27.16 27.16
Volume 665,100 665,100
Avg Vol 846,770 846,770
Stochastic %K 85.65% 85.65%
Weighted Alpha -29.37 -29.37
5-Day Change +3.37 (+13.25%) +3.37 (+13.25%)
52-Week Range 19.44 - 53.27 19.44 - 53.27
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,763,879
  • Shares Outstanding, K 64,944
  • Annual Sales, $ 47,070 K
  • Annual Income, $ -223,860 K
  • EBIT $ -262 M
  • EBITDA $ -268 M
  • 60-Month Beta 2.22
  • Price/Sales 35.83
  • Price/Cash Flow N/A
  • Price/Book 2.01

Options Overview Details

View History
  • Implied Volatility 101.59% ( -21.10%)
  • Historical Volatility 83.54%
  • IV Percentile 94%
  • IV Rank 61.13%
  • IV High 132.42% on 04/17/25
  • IV Low 53.10% on 11/27/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 22
  • Volume Avg (30-Day) 219
  • Put/Call OI Ratio 0.45
  • Today's Open Interest 2,955
  • Open Int (30-Day) 3,759

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.92
  • Number of Estimates 11
  • High Estimate -0.76
  • Low Estimate -1.07
  • Prior Year -0.69
  • Growth Rate Est. (year over year) -33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.44 +48.15%
on 04/09/25
Period Open: 32.54
35.28 -18.36%
on 03/24/25
-3.74 (-11.49%)
since 03/21/25
3-Month
19.44 +48.15%
on 04/09/25
Period Open: 44.13
45.31 -36.44%
on 01/27/25
-15.33 (-34.74%)
since 01/22/25
52-Week
19.44 +48.15%
on 04/09/25
Period Open: 34.35
53.27 -45.94%
on 09/26/24
-5.55 (-16.16%)
since 04/22/24

Most Recent Stories

More News
Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader

KYMR : 28.80 (+6.04%)
Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer

KYMR : 28.80 (+6.04%)
Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

KYMR : 28.80 (+6.04%)
Kymera Therapeutics to Participate in Upcoming March Investor Conferences

KYMR : 28.80 (+6.04%)
Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27

KYMR : 28.80 (+6.04%)
Kymera Therapeutics to Participate in Upcoming February Investor Conferences

KYMR : 28.80 (+6.04%)
Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

KYMR : 28.80 (+6.04%)
Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14

KYMR : 28.80 (+6.04%)
Insider Sale: Director at $KYMR (KYMR) Sells 2,500 Shares

Pamela Esposito, a director at $KYMR ($KYMR), sold 2,500 shares of the company on 12-02-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 100.0% of their shares....

KYMR : 28.80 (+6.04%)
Kymera Therapeutics to Participate in Upcoming December Investor Conferences

KYMR : 28.80 (+6.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Kymera Therapeutics Inc. is a biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics for degrade dysregulated, disease-causing proteins to address previously intractable disease targets. Kymera Therapeutics Inc. is based in Watertown, United States.

See More

Key Turning Points

3rd Resistance Point 30.82
2nd Resistance Point 29.89
1st Resistance Point 29.35
Last Price 28.80
1st Support Level 27.88
2nd Support Level 26.95
3rd Support Level 26.41

See More

52-Week High 53.27
Fibonacci 61.8% 40.35
Fibonacci 50% 36.35
Fibonacci 38.2% 32.36
Last Price 28.80
52-Week Low 19.44

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro